Metrics as of 10/14/2026, 03:38 PM (Berlin time), refresh in progress.
Taysha Gene Therapies Stock
Taysha Gene Therapies, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Sean Nolan
- Employees
- 99
- Market cap
- $1.1 B
- IPO
- 24/09/2020
Taysha Gene Therapies, Inc. is a biotechnology company in the healthcare sector based in Dallas, Texas, USA. Founded in 2019, the firm specializes in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. The core mission of the company is to tackle inherited diseases…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Taysha Gene Therapies stock: price history
1D
-0.7%
1W
-19.8%
1M
-29.0%
6M
-40.8%
YTD
-35.4%
1Y
-31.1%
2Y
+78.6%
5Y
-80.1%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~94% stronger price swings than usual
Ask the agents about Taysha Gene Therapies
Analyst assessment of Taysha Gene Therapies
PRICE TARGET LOW
US$13.00
CONSENSUS
US$14.00
MEDIAN
US$14.00
PRICE TARGET HIGH
US$15.00
0
STRONG BUY
15
BUY
3
HOLD
0
SELL
0
STRONG SELL
18
TOTAL · Buy
As of: 21/07/2026
Taysha Gene Therapies stock metrics
P/E
-8.41
P/B
3.39
EV/EBITDA
-4.95
RETURN ON EQUITY
-12.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.14
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
82.9%
FLOAT SHARES
265,141,739
AVG. DAILY VOLUME (30D)
4,104,112
Insider transactions (SEC)
Nagendran Sukumar
Donenberg Phillip B.
Stalfort John A III
Sepp-Lorenzino Laura
Long Alison S
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -0.7%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Taysha Gene Therapies stock
What does Taysha Gene Therapies do?
Taysha Gene Therapies, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Sean Nolan, the company employs around 99 people.
The IPO was on 24/09/2020; the stock trades on NASDAQ under the ticker TSHA.
What do analysts say about Taysha Gene Therapies stock?
18 analysts rate the stock, the consensus is Buy (as of 21/07/2026).
The average price target is US$14.00, ranging from US$13.00 to US$15.00, with a median of US$14.00.
This is an external assessment, not a statement by Market Jury.
When does Taysha Gene Therapies report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 94% stronger than usual.
Does Taysha Gene Therapies pay a dividend?
No, Taysha Gene Therapies currently does not pay a dividend.
Which stocks are comparable to Taysha Gene Therapies?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Taysha Gene Therapies stock analyzed?
Clicking "Analyze stock" lets five strategies assess Taysha Gene Therapies against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.